Articles from Stevanato Group S.p.A.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the second quarter of 2024 on Tuesday, August 6, 2024, at 6:30 a.m. (ET).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Mr. Moro will remain on the Company’s Board of Directors.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders (“AGM”) held virtually on May 22, 2024, have passed.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2024.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Bank of America Securities Healthcare Conference taking place from Tuesday, May 14, 2024 to Thursday, May 16, 2024.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).

Stevanato Group S.p.A. (NYSESTVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previously announced upsized underwritten public offering of an aggregate of 14,605,000 of its ordinary shares, which includes the full exercise of the underwriters’ option to purchase 1,905,000 additional ordinary shares, at a public offering price of $26.00 per share.

Stevanato Group S.p.A. (NYSESTVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.

Stevanato Group S.p.A. (NYSESTVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum taking place from Tuesday, March 19, 2024 to Wednesday, March 20, 2024.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2023.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30 a.m. (ET).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, unveiled today two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill® Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers (TEC).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8, 2024 to January 11, 2024 in San Francisco, California.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Jefferies London Healthcare Conference taking place from November 14, 2023 to November 16, 2023.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2023.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2023 on Tuesday, October 31, 2023, at 6:30 a.m. (ET).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announced today that the resolution proposed to shareholders at the Extraordinary General Meeting of Shareholders (“EGM”) held virtually on October 4, 2023 was passed.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2023.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2023 on Friday, July 28, 2023, at 6:30 a.m. (ET).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, unveiled today Vertiva™, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with New York Stock Exchange rules. The new ex-dividend date for the dividend will be June 7, 2023, and the record date remains June 6, 2023. The dividend will continue to be payable on July 17, 2023.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2023, and maintained its fiscal 2023 guidance.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the upcoming BofA Securities Healthcare Conference at the Encore hotel in Las Vegas that will take place from May 9, 2023 to May 11, 2023.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2023 on Thursday, May 4, 2023, at 6:30 a.m. (ET).

Stevanato Group S.p.A. (NYSESTVN) a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today its collaboration with Thermo Fisher Scientific, the world leader in serving science, to bring to the market a fully integrated on-body delivery system platform for subcutaneous administration.

Stevanato Group S.p.A. (NYSESTVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with leading Contract Development and Manufacturing Organisation (CDMO), Recipharm. Under the agreement, Stevanato Group will lend its 70+ years of manufacturing experience to support the development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers. As part of this collaboration, Stevanato Group will provide and manufacture its glass pre-fillable syringe Alba® assembled with the Integrated Spray Module (ISMTM) of Recipharm’s soft mist inhaler technology, the Pre-Filled Syringe Inhaler (PFSITM).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum taking place on March 21 and March 22, 2023.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2022, and established fiscal 2023 guidance.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2022 on Thursday, March 2, 2023, at 6:30 a.m. (ET).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced its latest collaboration with Transcoject GmbH, a medical device and pharma packaging solutions company. The collaboration will enable Stevanato Group to add cyclic olefin polymer (COP) and cyclic olefin copolymer (COC) PFS to its existing portfolio of solutions providing added value in the customers’ supply chain.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that management will present at the Jefferies London Healthcare Conference at 12:55 p.m. (GMT) on November 17, 2022.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2022.

Stevanato Group S.p.A. (NYSESTVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics, announced today at CPhl Worldwide the official launch of a new and innovative ready-to-use (RTU) vial platform, EZ-fill Smart™, a solution designed to improve drug packaging quality, reduce total cost of ownership (TCO), and shorten lead times for customers. The new EZ-fill Smart™ is an evolution of Stevanato Group’s groundbreaking EZ-fill® platform, and it brings new advancements that can create significant enhancements to customer product offerings amid growing demand for RTU vials.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, and DWK Life Sciences, a leading global manufacturer and provider of precision labware as well as primary packaging solutions for Life Science Research, Diagnostics and Pharmaceutical markets, today announced they have entered a non-exclusive agreement for the distribution and sale of the EZ-fill® Ready-to-Use solutions (RTU) by Stevanato Group.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2022 on Tuesday, November 8, 2022, at 6:30 a.m. (ET).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that management will present at the Bank of America Global Healthcare Conference in London at 9:05 a.m. (BST) on September 15, 2022.

Stevanato Group S.p.A. (NYSESTVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics, announce that they have jointly developed a high-end Ready-To-Use (RTU) solution platform with an initial focus on vials, based on Stevanato Group’s market-leading EZ-fill® technology. This collaboration is projected to help customers gain efficiencies, improve the quality standard, increase speed to market, reduce total cost of ownership (TCO) and help mitigate supply chain risk.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2022.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2022 on Thursday, August 4, 2022, at 6:30 a.m. (EST).

Stevanato Group S.p.A. (NYSESTVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announces the publication of its Sustainability Report 2021. The report showcases the Group’s holistic approach to sustainable development and highlighted strong guidance aimed at pursuing goals pertaining to economic sustainability, its responsibility to innovation and new products, employees, and the environment.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announced today that all resolutions proposed to Shareholders at the Annual General Meeting of Shareholders (“AGM”) held virtually on June 1, 2022 were passed.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences.

Stevanato Group S.p.A. (NYSESTVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced the acquisition of a new industrial complex in Cisterna di Latina, Italy. The new facility is expected to strengthen Stevanato Group’s presence in Europe and expand the Company’s production capabilities to satisfy increased demand for its standard and premium products from high-growth customers.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2022.

Stevanato Group S.p.A. (NYSESTVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an exclusive agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for its Aidaptus® auto-injector.

Italian-based Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Bexson Biomedical, Inc., a research stage company developing subcutaneous therapies for pain management and mental health disorders, announced today that they have signed an agreement expanding their collaboration.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the first quarter of 2022 on Tuesday, May 10, 2022, at 6:30 a.m. Eastern Time (12:30 Central European Time).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced the filing of Amendment No. 1 (the “Form 20-F/A”) to its 2021 Annual Report on Form 20-F (the “Form 20-F”), which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 8, 2022, to submit the Interactive Data File and to provide certain additional information as described in the explanatory note thereto.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Management will present virtually at 9:00 a.m. EDT on Tuesday, March 22, 2022.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the fourth quarter and full year of fiscal year 2021 on Tuesday, March 8, 2022, at 6:30 a.m. Eastern Time (12:30 Central European Time).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the third quarter of fiscal 2021 on Tuesday, November 9, 2021 at 6:30 a.m. Eastern Time (12:30 CET).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter 2021 and established full-year 2021 guidance.

Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that the underwriters of the Company’s recently completed initial public offering of its ordinary shares have exercised in part their option to acquire an additional 1,018,280 ordinary shares at $21 a share.

Stevanato Group S.p.A. (NYSESTVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the second quarter of fiscal year 2021 on Thursday, August 19, 2021.

Stevanato Group S.p.A. (the “Company”) today celebrates its debut on the New York Stock Exchange under the ticker symbol “STVN.” Founded by Giovanni Stevanato in 1949, the Company is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.

Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its initial public offering of 32,000,000 of its ordinary shares at a price of $21 per share.

Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it plans to commence the roadshow for its proposed initial public offering of 40,000,000 ordinary shares.

Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of its ordinary shares (the “Offering”). A portion of the ordinary shares will be issued and sold by the Company and a portion will be sold by its shareholder Stevanato Holding S.r.l. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The Offering is subject to market conditions, and there can be no assurance as to whether, or when, the Offering may be completed or as to the actual size or terms of the Offering. The Company intends to list its ordinary shares on the New York Stock Exchange under the symbol STVN.